The antibody drug conjugates market was valued at $1,387 million in 2016, and is estimated to reach $3,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023. Antibody drug conjugates (ADC’s) are promising and effective anticancer medications employed for efficient treatment of cancer patients. ADC’s are biopharmaceutical drugs prepared by integrating two clinical approaches viz cell killing HPAPI (powerful pharmaceutical ingredient) and monoclonal antibody specificity. This combination approach enables elimination of cancer infected cells without harming healthy cells in patient’s body. Research Beam Model: Research Beam Product ID: 2019221 5370 USD New
Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023

 
  • Category : Healthcare
  • Published On : September  2017
  • Pages : 152
 
 

The antibody drug conjugates market was valued at $1,387 million in 2016, and is estimated to reach $3,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023. Antibody drug conjugates (ADC’s) are promising and effective anticancer medications employed for efficient treatment of cancer patients. ADC’s are biopharmaceutical drugs prepared by integrating two clinical approaches viz cell killing HPAPI (powerful pharmaceutical ingredient) and monoclonal antibody specificity. This combination approach enables elimination of cancer infected cells without harming healthy cells in patient’s body. 

Increase in global prevalence of cancer and demand for quality & cost-effective cancer medications drives the global ADCs market. In addition, extensive R&D for cancer medication and approval of new cancer drugs is expected to boost the market growth during the forecast period. However, high cost involved in R&D of cancer medication and stringent government regulations impedes the growth of antibody drug conjugates market. 

The report segments the market based on drugs, mechanism of action, application, and region. Based on drugs, the market is bifurcated into Adcetris and Kadcyla. Based on mechanism of action, it is divided into CD30 antibodies and HER2 antibodies. Based on application, the market is classified into breast cancer, lymphoma, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS

  •  The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  •  It offers a quantitative analysis from 2017 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  •  Extensive analysis by product elucidates the various types of ADC’s used for diverse cancer therapeutic procedures
  •  Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  •  Key players are profiled and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the global ADCs market.

KEY PLAYERS PROFILED

  •  F. Hoffman-La Roche Ltd.
  •  Novartis AG
  •  Takeda Pharmaceutical Company Limited
  •  Pfizer, Inc.
  •  Seattle Genetics Inc.
  •  Genentech Inc.
  •  Immunogen Inc.
  •  Immunomedics, Inc.
  •  Progenics Pharmaceuticals Inc. 
  •  Bayer AG

KEY MARKET SEGMENTS

BY DRUGS

  •  Adcetris 
  •  Kadcyla

BY MECHANISM OF ACTION

  •  CD30 Antibodies
  •  HER2 Antibodies

BY APPLICATION

  •  Breast Cancer
  •  Lymphoma

By Region

  •  North America
    •  U.S.
    •  Canada
    •  Mexico
  •  Europe
    •  France 
    •  Germany 
    •  UK 
    •  Italy 
    •  Spain 
    •  The Netherlands 
    •  Norway
    •  Russia 
    •  Sweden
    •  Switzerland 
    •  Rest of Europe
  •  Asia-Pacific
    •  Japan 
    •  China 
    •  India 
    •  Australia 
    •  South Korea 
    •  New Zealand 
    •  Taiwan 
    •  Thailand 
    •  Rest of Asia-Pacific 
  •  LAMEA
    •  Brazil 
    •  Saudi Arabia 
    •  South Africa 
    •  Chile 
    •  Columbia 
    •  Egypt 
    •  Iran 
    •  Israel 
    •  Turkey 
    •  Venezuela 
    •  Rest of LAMEA 

The other players of the anesthesia market include (companies not profiled in the report):

  •  Agensys, Inc. 
  •  Concortis Biotherapeutics
  •  Sanofi S.A.
  •  Celldex Therapeutics Inc. 
  •  Synthon Holding B.V.

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. TOP PLAYER POSITIONING
3.4. PATENTS ANALYSIS

3.4.1. Patent analysis by year
3.4.2. Patent analysis by region

3.5. PORTERS FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS

4.1. OVERVIEW

4.1.1. Market size & forecast

4.2. ADCETRIS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size & forecast

4.3. KADCYLA

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size & forecast

CHAPTER 5 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION

5.1. OVERVIEW

5.1.1. Market size & forecast

5.2. CD30 ANTIBODIES

5.2.1. Market size & forecast

5.3. HER2 ANTIBODIES

5.3.1. Market size & forecast

CHAPTER 6 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION

6.1. OVERVIEW

6.1.1. Market size & forecast

6.2. BREAST CANCER

6.2.1. Market size & forecast

6.3. LYMPHOMA

6.3.1. Market size & forecast

CHAPTER 7 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY GEOGRAPHY

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size & forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size & forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.5. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size & forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. South Korea market size and forecast
7.4.3.5. Taiwan market size and forecast
7.4.3.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size & forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. Saudi Arabia market size and forecast
7.5.3.4. South Africa market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. PFIZER, INC.

8.1.1. Operating business segments
8.1.2. Business performance

8.2. CELLDEX THERAPEUTICS INC.

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. SEATTLE GENETICS INC.

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. GENENTECH INC.

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. IMMUNOGEN INC.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.5. SANOFI S.A.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.7. IMMUNOMEDICS, INC.

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. PROGENICS PHARMACEUTICALS INC.

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.8. BAYER HEALTHCARE PHARMACEUTICALS

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.10. SYNTHON HOLDING B.V.

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)
TABLE 2. ADCETRIS ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 3. KADCYLA ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)
TABLE 5. CD30 ANTIBODIES ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 6. HER2 ANTIBODIES ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 8. BREAST CANCER ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 9. LYMPHOMA ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 10. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 11. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)
TABLE 12. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)
TABLE 13. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)
TABLE 14. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 15. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)
TABLE 16. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)
TABLE 17. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)
TABLE 18. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)
TABLE 20. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)
TABLE 21. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)
TABLE 22. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)
TABLE 24. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)
TABLE 25. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)
TABLE 26. PFIZER, INC.: COMPANY SNAPSHOT
TABLE 27. PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 28. CELLDEX THERAPEUTICS INC: COMPANY SNAPSHOT
TABLE 29. CELLDEX THERAPEUTICS INC: PRODUCT PORTFOLIO
TABLE 30. SEATTLE GENETICS INC: COMPANY SNAPSHOT
TABLE 31. SEATTLE GENETICS INC: PRODUCT PORTFOLIO
TABLE 32. GENENTECH INC: COMPANY SNAPSHOT
TABLE 33. GENENTECH INC: PRODUCT PORTFOLIO
TABLE 34. IMMUNOGEN INC: COMPANY SNAPSHOT
TABLE 35. IMMUNOGEN INC: PRODUCT PORTFOLIO
TABLE 36. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 37. SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 38. IMMUNOMEDICS, INC: COMPANY SNAPSHOT
TABLE 39. IMMUNOMEDICS, INC: PRODUCT PORTFOLIO
TABLE 40. PROGENICS PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 41. PROGENICS PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 42. BAYER HEALTHCARE PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 43. BAYER HEALTHCARE PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 44. SYNTHON HOLDING B.V.: COMPANY SNAPSHOT
TABLE 45. SYNTHON HOLDING B.V.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. ANTIBODY DRUG CONJUGATES MARKET: MARKET SEGMENATION
FIGURE 2. TOP INVESTMENT POCKETS: GLOBAL DNA SEQUENCING MARKET, BY APPLICATION
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 5. TOP PLAYER POSITIONING: GLOBAL ANTIBODY DRUG CONJUGATES MARKET
FIGURE 7. PATENT ANALYSIS BY YEAR
FIGURE 8. PATENT ANALYSIS BY REGION
FIGURE 9. BARGAINING POWER OF BUYERS
FIGURE 10. BARGAINING POWER OF SUPPLIERS
FIGURE 11. THREAT OF NEW ENTRANTS
FIGURE 12. THREAT OF SUBSTITUTION
FIGURE 13. COMPETITIVE RIVALRY
FIGURE 14. ANTIBODY DRUG CONJUGATES MARKET: DRUGS SEGMENATION
FIGURE 15. ANTIBODY DRUG CONJUGATES MARKET: MECHANISM OF ACTION SEGMENATION
FIGURE 16. ANTIBODY DRUG CONJUGATES MARKET: BY APPLICATION SEGMENATION
FIGURE 17. U.S. ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 18. CANADA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 19. MEXICO ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 20. GERMANY ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 21. FRANCE ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 22. UK ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 23. ITALY ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 24. SPAIN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 25. REST OF EUROPE ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 26. JAPAN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 27. CHINA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 28. AUSTRALIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 29. INDIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 30. SOUTH KOREA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 31. TAIWAN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 32. REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 33. BRAZIL ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 34. TURKEY ANTIBODY DRUG CONJUGATES MARKET, 2016-20223 ($MILLION)
FIGURE 35. SAUDI ARABIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 36. SOUTH AFRICA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 37. REST OF LAMEA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)